Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16271
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChen, Emily C-
dc.contributor.authorPapa, Nathan P-
dc.contributor.authorLawrentschuk, Nathan-
dc.contributor.authorBolton, Damien M-
dc.contributor.authorSengupta, Shomik-
dc.date2015-10-21-
dc.date.accessioned2016-09-15T05:39:36Z-
dc.date.available2016-09-15T05:39:36Z-
dc.date.issued2016-04-
dc.identifier.citationBJU International 2016; 117(S4): 50-53en_US
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/16271-
dc.description.abstractOBJECTIVE: To determine the incidence and assess risk factors for the development of VTE among patients undergoing major pelvic surgery for prostate and bladder cancer in an Australian tertiary referral center. PATIENTS AND METHODS: Consecutive patients undergoing major pelvic uro-oncologic surgery, namely radical cystectomy and radical prostatectomy over a five-year period (2009-2013) were identified. Patient variables and types of thromboprophylaxis (pharmacological and/or mechanical) used in this patient cohort were collected for analyses as predictive factors. RESULTS: The overall incidence of VTE was 1.8%. Patients undergoing radical cystectomy were more likely to suffer a VTE event compared to patients having radical prostatectomy. In this cohort, the risk factors for VTE include, prolonged operative time of greater than 4 hours (h), lymph node dissection (LND) and patients requiring blood transfusions. CONCLUSION: Patients undergoing major pelvic uro-oncologic surgery have an approximately 1.8% risk of developing VTE. Risk factors identified in this study should be used to guide the use of early and prolonged thromboprophylaxis.en_US
dc.subjectThromboprophylaxisen_US
dc.subjectUro-oncologic surgeryen_US
dc.subjectVenous thromboembolismen_US
dc.titleIncidence and risk factors of venous thromboembolism after pelvic uro-oncologic surgery - a single center experienceen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleBJU Internationalen_US
dc.identifier.affiliationUniversity of Melbourne, Department of Surgery, Austin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationUrology Unit, Austin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Austin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australiaen_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/26486818en_US
dc.identifier.doi10.1111/bju.13238en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0002-3188-1803en_US
dc.identifier.orcid0000-0001-8553-5618en_US
dc.identifier.orcid0000-0002-5145-6783en_US
dc.type.austinJournal Articleen_US
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
crisitem.author.deptUrology-
crisitem.author.deptUrology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

2
checked on Feb 1, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.